A Nigerian biomedical researcher, Ibrahim Oladele, is developing an innovative drug delivery system that could significantly improve treatment outcomes for patients with deadly cancers such as glioblastoma and breast cancer.
According to a statement made available to newsmen, Oladele, who is currently completing his Ph.D. in Applied Science with a concentration in Biosciences at the University of Arkansas at Little Rock, is conducting his research at the Center for Integrative Nanotechnology Sciences.
His work focuses on creating a sustained-release, targeted cancer drug delivery system using polyethylene glycol (PEG) and gold nanoparticles.
The research aims to deliver cancer drugs more precisely to tumours, potentially increasing treatment effectiveness while reducing side effects and costs for patients.
Oladele’s system involves a three-pronged approach: studying how PEG interacts with cancer and immune cells, designing targeting mechanisms to direct the drugs to tumour sites, and cloaking the therapy in cell membranes to avoid detection by the immune system.
According to the statement, his interest in cancer research began in 2018, following the death of a neighbour from the disease. This experience led him to pursue a master’s degree in Biomedicine, with a specialisation in translational cancer research, at the University of Barcelona, Spain.
Oladele’s work has already gained attention within the scientific community. He was recently nominated to present his research at the Society for Neuroscience (SfN) conference in Washington, D.C. He is also a member of the American Association for Cancer Research and the Society for Neuroscience.
He has also contributed to science education, serving as a teaching assistant in microbiology, anatomy, and physiology, and mentoring future medical and graduate students.
He stated that his mission is to ensure science serves people directly, adding that his goal is not just academic progress but practical solutions that can improve lives.
and then